Colorectal cancer is thought to be more common in men than in women. The chromosomal locations of DNA gains and losses in surgical specimens of colorectal tumours were detected by comparative genomic hybridization and were compared by gender. Five chromosomal regions, 7p, 8p, 8q, Xp and Xq, contained multiple gains that were significantly more common in males than in females, and within these regions, the differences were significant for Xp21, Xp11.3, Xp11.4 and Xq26. Regions 1p, 3q, 11q, 12p, 12q and 15q contained multiple sites of gain that were significantly more common in females than in males. Tumours from male and female patients showed significantly more losses at 11p and 15q, and at 4q and Xq, respectively. The fact that gains in X-chromosomal regions were detected with a significantly higher frequency in tumours from male patients suggests that the difference between the genders might be explained by X-chromosomal inactivation.
Introduction
Genetic instability is thought to be instrumental in cancer initiation and progression, and many studies have attempted to determine the biological behaviour of cancers from the viewpoint of gene expression. 1 The mechanism of oncogenesis in colon cancer has been widely studied; for example, Vogelstein et al. 2 have researched the genetic alterations during colorectal-tumour development.
A molecular cytogenetic procedure called comparative genomic hybridization (CGH) was developed by Kallioniemi et al. 3 in 1992 on the basis of the conventional fluorescence in situ hybridization (FISH). The method allows simultaneous detection of genomic copy-number aberrations at the chromosomal level in solid tumours, for which gene analysis has been difficult. The technique also allows identification of the regions of aberration on any chromosome. Basically, it allows detection of DNA sequence copy-number changes throughout the genome by co-hybridization of differentially labelled tumour and normal Sex and chromosomal aberrations in colorectal cancer (the reference) DNA to human metaphase chromosomes. The DNA gains and losses, and their locations are then analysed.
As colorectal cancer is thought to be more common in male than in female patients, chromosomal gains and losses detected by CGH were compared by gender to determine whether there were any differences.
Patients and methods

PATIENTS
Tumours for genetic analysis were obtained from males and females who had undergone surgical operations to remove colorectal cancer. Prior informed consent was obtained, and the study was approved by the Ethics Committee of Juntendo University School of Medicine.
SPECIMENS
Tissue from each primary tumour was embedded in Optimal Cutting Temperature (OCT) Compound (No. 4583; Sakura Finetek, Torrance, CA, USA). The frozen specimen was sliced at 16 µm using Cryostat HM550-OMVP (Zeiss, Oberkochen, Germany) and each slice was put onto a MAS-coated glass slide (No. 818; Matsunami Glass Co., Osaka, Japan). The specimen was stained with HistoGene Staining Solution (No. AL304S; Takara BIO Inc., Shiga, Japan) and was examined under an inverted microscope (CKX-41-31-PHP; Olympus Co., Tokyo, Japan) in order to collect cancer cells by microdissection. From the cancer cells collected, genomic DNA was extracted using the QIAamp DNA Micro Kit (Qiagen GmbH, Hilden, Germany). Electrophoresis on 0.8% agarose gel was conducted to confirm the size of the genomes.
COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS
The genomes were labelled with the Nick Translation Kit (No. VYS-32-801300; Vysis Inc., Downers Grove, IL, USA). Fluorescent labelling was performed using 1 µl of tumour DNA, 5 µl of 0.1 mM dTTP (2′-deoxythymidine-5′-triphosphate) (Vysis Inc.), 10 µl of 0.1 mM dNTP (deoxyribonucleotide triphosphate) (Vysis Inc.), 5 µl of 10 × Nick translation buffer, 5 µl of spectrum green-dUTP (2′-deoxyuridine-5′-triphosphate) (No. VYS-30-803200; Vysis Inc.) and 10 µl of Nick translation enzyme. Using 1 µl of normal DNA (Human Male Genomic DNA; Novagen No. 7057-3; or Human Female Genomic DNA; Novagen No. 7065-3; EMD Bio Sciences Inc., Darmstadt, Germany), fluorescent labelling was performed in the same manner using 5 µl of Spectrum Red-dUTP (No. VYS-30-803400; Vysis Inc.).
Ethanol precipitation was carried out by mixing 25 µl of spectrum green-labelled DNA, 25 µl of spectrum red-labelled DNA, 10 µl of human COT-1 DNA (No. 1582011; Roche Co., Basel, Switzerland), 6 µl of 3M sodium acetate and 150 µl of 100% ethanol. The precipitate was dried and dissolved in 7 µl of CGH Hybridization Buffer (No. VYS-32-804828; Vysis Inc.). It was denatured at 37°C for 30 min, 45°C for 6 min 20 s and 75°C for 6 min, and allowed to stand in ice. After the probe solution was placed on the slide of denatured lymphocyte metaphase chromosomes derived from normal human male (CGH Metaphase Target Slide, No. VYS-30-806010; Vysis Inc.), the preparation was sealed, allowed to stand on a slide warmer set at 37°C for 1 h, and subjected to a 48-h hybridization in an incubator. The slide was washed and dried, and 10 µl of DAPI II (4′,6-diamidino-2-phenylindole) counterstain (No. VYS-32-804831; Vysis Inc.) was dropped onto the target to perform counterstaining.
The fluorescent images of chromosomes were digitized by individually capturing red, green and DAPI images using a fluorescent J Unotoro, H Kamiyama, Y Ishido et al.
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microscope with a charge-coupled device camera (No. DM5000B; Leika Microsystems, Tokyo). CW4000 Karyo software (Leika Microsystems) was used for CGH analysis. On the basis of the stained images obtained by DAPI counterstaining and the chromosome size, 22 autosomes and X and Y chromosomes were identified. Intensity curves of green and red fluorescence were generated along the long axis of each chromosome, and the ratio of the intensity of red : green fluorescence was calculated. A ratio of 1.0 was set as the baseline. A copy number of 0.8 and below was assessed as DNA copy-number loss, and a copy number of 1.2 and above was assessed as DNA copynumber gain.
Gender differences in the clinical and histopathological features of the accumulated cases and chromosome aberrations were evaluated.
STATISTICAL ANALYSIS
Statistical analysis was performed using Fisher's exact test and P-values of < 0.05 were considered to be statistically significant. The Japanese version of StatView version 5.0 (HULINKS, Tokyo) was used for the analysis.
Results
Tumour samples from 46 patients (21 male, 25 female) were collected for genetic analysis at the Department of Coloproctological Surgery, Juntendo University School of Medicine, Japan, between April 2003 and December 2004.
No statistically significant difference was detected between the male and female patients with respect to age, histological tumour type, depth of penetration, primary site, degree of blood vessel invasion, lymphatic vessel invasion, lymph-node metastasis, presence or absence of liver metastasis, presence or absence of lung metastasis, or histopathological stage (Dukes' classification) ( Table 1) .
Tumours from male patients showed significantly more gains (P < 0.05) in chromosomal regions 7p, 8p, 8q, Xp and Xq compared with those from females ( Fig. 1 ). Within these regions, the difference was significant at P < 0.001 for Xp21, Xp11.3, Xp11.4 and Xq26 and at P < 0.05 for all the remaining regions ( Table 2 ). Female patients showed significantly more gains (P < 0.05) in chromosomal regions 1p, 3q, 11q, 12p, 12q and 15q, and the difference was significant at P < 0.001 for 12q24.1 only ( Table 2) . Tumours from male patients showed significantly more losses (P < 0.05) in chromosomal regions 11p and 15q, while those from females showed significantly more losses (P < 0.05) in chromosomal regions 4q and Xq (Table 3) . A total of 394 distinct chromosomal regions were examined.
Discussion
The CGH method is an excellent means of simultaneously detecting regions of gain or loss of DNA sequences and producing a map of copy number as a function of chromosomal location throughout the entire genome. It has been used by numerous other investigators. For example, De Angelis et al. 1 detected a relative copy-number abnormality in an average of seven regions using CGH analysis of non-familial colorectal carcinomas in 45 patients. The frequency of aberrations involving gains was high at 5p, 6p, 7, 8q, 13q 17q, 18q, 19, 20q and X, whereas losses were common at 1p, 3p, 4, 5q, 6q, 8p, 9p, 10, 15q and 17p. Four regions in which gains were significantly more common for males in the present study, 7p, 8q, Xp and Xq, were the locations of frequent gains in the study by De Angelis et al. 1 According to Motokami et al., 4 Rs, rectosigmoid colon; Ra, rectum, above the peritoneal reflection; Rb, rectum, below the peritoneal reflection; well, well-differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma; muc, mucinous adenocarcinoma; m, mucosa; sm, submucosa; mp, muscularis propria; ss(a1), subserosa, but not through serosa (no serosa); se(a2), invades through serosa into free peritoneal cavity (no serosa); si(ai), invades through serosa into contiguous organs (no serosa); pN stage, degree of histopathological lymph node metastasis; ly degree of histopathological lymphatic vessel invasion; v, degree of histopathological blood vessel invasion; NS, not significant. the four regions, 7p, 8q, Xp and Xq, generally take the form of gains, and gains in the short and long arms of chromosome 7 are frequently detected in colorectal, prostate, and breast cancers. Gains of genes on chromosome 7 are frequent in metastatic colorectal cancer and recurrent prostate cancer; for example, the gene EGFR for the epidermal growth factor receptor is reportedly located at 7p. 1 Gain of an extensive region of the long arm of chromosome 8 is characteristic of human cancer; this is assumed to be the location of most frequent aberrations in all cancers; for instance, c-myc, an oncogene, is located at 8q24. 1 The X chromosome shows frequent gains over an extensive region in the short and long arms. 4 This study found that region 12q24.1 was one of the regions in which gains were significantly more common (P < 0.001) for females. The Cancer Genetics Web 5 shows that insulin-like growth factor 1 is at 12q22 -q24.1 in colorectal cancer. This gene participates in phosphorylation of the oestrogen and progesterone receptors in breast cancer by activating these receptors. 6 It may be hypothesized that hormone receptors play a greater role in the development of colorectal cancer in women than in men.
aberrations in
As a breakdown of gains and losses at the sites shows (Table 4 ), no losses in these chromosomes were seen in tumours from male patients. Generally, in cancers, the X chromosome shows gains over a wide region of both the short and the long arms, and correlation between X-chromosome aberration and cancer development has been detected by CGH analysis in various cancers. 4 For instance, in bilateral breast cancer, DNA copy-number changes were detected asynchronously and synchronously in 9.0% and 3.1% of tumours, respectively, by cDNA array-based CGH. 7 Terracciano et al. 8 reported that the most common aberrations were Xp gains (in 43%) and Xq gains (in 60%) in a CGH analysis of 35 hepatoblastomas. In a CGH analysis of chronic lymphocytic leukaemia, gains and losses at Xp11.2, Xp21 and Xq21 tended to be more distinct in the 24 familial than in sporadic cases. 9 Among the X-chromosomal regions where males showed more gains at P < 0.001, 
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Cancer Genetics Web 5 shows that Xp11.4 is the location of ARAF1, the v-raf murine sarcoma 3611 viral oncogene homologue 1 gene. This gene encodes a cytoplasmic protein, serine/threonine kinase, which plays an important role in the proliferation and development of cells. 10 There is a possibility that this finding is related to the gender difference in the incidence of colorectal cancer. Indeed, it was at Xp21, Xp11.3, Xp11.4 and Xq26 that males showed a significantly higher level of gains. This finding suggests that the high level of gains is related to X-chromosomal inactivation.
One of the two X chromosomes is inactivated early in the cells of females. Consequently, the normal tissues of females with heterologous genes show a mosaic pattern, in which roughly half of the cells express one of the two alleles while the rest express the other. 11 In roughly half of the cells in females, one of the X chromosomes is inactivated, and a specific X-chromosome aberration will not be manifest. In males, on the other hand, there is no homologous X chromosome, so the sole X chromosome is active, and sex-linked recessive hereditary disorders are more likely to be expressed. It is possible that in male patients, expression of oncogenes carried on the X chromosome that are related to colorectal cancer is more likely to take the form of copy-number aberrations, and this might account for the relatively higher incidence of colorectal cancer in males than in females.
The chromosomal gains and losses detected by CGH were compared by gender to determine whether there were any differences. Tumours from male patients showed a significantly greater number of gains in regions 7p, 8p, 8q, Xp and Xq, and four of these (7p, 8q, Xp and Xq) are the regions where more gains are detected in the CGH analysis of general non-familial colorectal cancer. This may be related to the higher incidence of colorectal cancer in men that has been shown by epidemiological studies, although the possibility that the difference was the result of chance cannot be ruled out completely. Males showed a significantly higher level of gains (P < 0.001) at Xp21, Xp11.3, Xp11.4 and Xq26, suggesting that the difference between sexes in the frequency of colorectal cancer can be explained by X-chromosomal inactivation.
Some of the abnormal genes related to the gender difference in the development of colorectal cancer may be located in the above regions. These abnormal genes might be identified from the locations of chromosomal aberrations, and this fact may lead to clinical application.
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